Jane Street’s FibroBiologics FBLG Stock Holding History

Jane Street’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,488	Closed	-$33.7K	–	13195
2025 Q4	$33.7K	Buy	+7,488	New	+$52.7K	﹤0.01%	10620
2025 Q3	–	Sell	-4,806	Closed	-$59.8K	–	11942
2025 Q2	$59.8K	Buy	+4,806	New	+$86.7K	﹤0.01%	9125
2025 Q1	–	Sell	-3,054	Closed	-$122K	–	10827
2024 Q4	$122K	Buy	3,054 +2,461	+415%	+$132K	﹤0.01%	8674
2024 Q3	$36.6K	Buy	+593	New	+$39.4K	﹤0.01%	9215

Other funds holding FBLG

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FEG

Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

VGA

Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Jane Street's FBLG Position: Q1 2026 in Review

Jane Street sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 7,488 shares — an estimated $33.7K sold.

Jane Street first reported a position in FBLG in Q3 2024 and held it in 4 quarters. The position peaked at $122K in Q4 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

Jane Street reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
Jane Street sold 7,488 FibroBiologics shares in Q1 2026, an estimated $33.7K.
Jane Street first reported a position in FibroBiologics in Q3 2024 and held it in 4 quarters.
Jane Street's FibroBiologics position peaked at $122K in Q4 2024.
17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.